The BIOSECURE Act, once passed, will mark a pivotal shift in US biotechnology policy, addressing critical national security priorities. It will demand swift responses from companies and investors in the life sciences sectors.

Listen to our discussion with guest speaker Evan Chuck from Crowell & Moring LLP and learn more about:

  • the certainties and uncertainties of the BIOSECURE ACT;
  • the possible impact on global supply chains and development of drugs;
  • the potential strategies to safeguard interests and secure continued innovation and collaboration.

Whether you are a pharmaceutical or biotech company; a supply chain partner or research institution, this webinar is aimed at delivering essential insights for navigating this novel and complex landscape.